GOLDMAN SACHS GROUP INC - TRILLIUM THERAPEUTICS INC ownership

TRILLIUM THERAPEUTICS INC's ticker is and the CUSIP is 89620X506. A total of 137 filers reported holding TRILLIUM THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.33 and the average weighting 0.4%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of TRILLIUM THERAPEUTICS INC
ValueSharesWeighting
Q3 2021$22,191,000
+356.2%
1,263,721
+152.0%
0.01%
+400.0%
Q2 2021$4,864,000
+340.6%
501,442
+387.4%
0.00%
Q1 2021$1,104,000
-86.7%
102,875
-81.8%
0.00%
-100.0%
Q4 2020$8,326,000
+229.9%
566,042
+218.8%
0.00%
+200.0%
Q3 2020$2,524,000
+54.6%
177,561
-12.0%
0.00%
Q2 2020$1,633,000
+258.9%
201,833
+79.2%
0.00%
Q1 2020$455,000112,6510.00%
Other shareholders
TRILLIUM THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
NEA Management Company, LLC 2,100,000$646,0000.05%
Matrix Capital Management Company, LP 2,288,560$704,0000.02%
Tekla Capital Management LLC 446,099$137,0000.01%
Realta Investment Advisors 26,000$7,0000.00%
Virtu Financial LLC 34,991$11,0000.00%
Baker Brothers Advisors 505,262$155,0000.00%
BOOTHBAY FUND MANAGEMENT, LLC 20,044$6,0000.00%
MORGAN STANLEY 1,160,098$356,0000.00%
BANK OF MONTREAL /CAN/ 18,333$6,0000.00%
GEODE CAPITAL MANAGEMENT, LLC 102,725$31,0000.00%
View complete list of TRILLIUM THERAPEUTICS INC shareholders